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Abstract
Introduction: In many European countries, restrictions exist around the prescription of anti-tumor necrosis factor
(anti-TNF) treatments for rheumatoid arthritis (RA). Eligibility and response to treatment is assessed by using the
disease activity score 28 (DAS28) algorithm, which incorporates one of two inflammatory markers, erythrocyte
sedimentation rate (ESR) or C-reactive protein (CRP). Although DAS28-CRP provides a more reliable measure of
disease activity, functional variants exist within the CRP gene that affect basal CRP production.
Therefore, we aimed to determine the relation between functional genetic variants at the CRP gene locus and
levels of serum CRP in RA patients, and whether these variants, alone or in combination, are correlated with
DAS28-CRP and change in DAS28-CRP after anti-TNF treatment.
Methods: DNA samples from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate
(BRAGGSS) were genotyped for rs1205, rs1800947, and rs3091244 by using either TaqMan or the Sequenom
MassARRAY iPLEX system.
Estimated haplotypes were constructed for each sample by using the expectation maximization algorithm
implemented in the haplo.stats package within the R statistical program.
CRP values were log transformed, and the association between single nucleotide polymorphisms (SNPs),
haplotypes of SNPs and baseline CRP, baseline DAS28-CRP, and change in DAS28-CRP were evaluated by using
linear regression in STATA v.10.
Results: Baseline CRP measurements were available for 599 samples with 442 also having data 6 months after
treatment with an anti-TNF. For these 442 samples, the study had > 80% power to detect a clinically meaningful
difference of 0.6 DAS28 Units for an allele frequency of 5%. Estimated haplotype frequencies corresponded with
previous frequencies reported in the literature. Overall, no significant association was observed between any of the
markers investigated and baseline CRP levels. Further, CRP haplotypes did not correlate with baseline CRP (P =
0.593), baseline DAS28-CRP (P = 0.540), or change in DAS28-CRP after treatment with an anti-TNF over a 6-month
period (P = 0.302).
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Conclusions: Although CRP genotype may influence baseline CRP levels, in patients with very active disease, no
such association was found. This suggests that genetic variation at the CRP locus does not influence DAS28-CRP,
which may continue to be used in determining eligibility for and response to anti-TNF treatment, without
adjusting for CRP genotype.
Introduction
Rheumatoid arthritis (RA) is a chronic, systemic, auto-
immune disease that is characterized by synovial joint
inflammation and, when inflammation is persistent,
leads to the progressive destruction of joints [1,2].
One of the most exciting developments in the treatment
of RA has been the introduction and widespread use of
biologic drugs that block the tumor necrosis factor (TNF)-
a pathway (anti-TNF drugs). These drugs not only reduce
inflammation, but also halt radiologic damage and are
responsible for spearheading a major advance in the thera-
peutic options available for RA patients [3]. However,
limitations are associated with the use of biologic treat-
ments, including the high costs (approximately £10,000
per patient per year), inefficacy in a significant minority of
patients, and the increased risk of infection [4]. In the UK,
eligibility for biologics is determined by guidance issued by
the National Institute of Health and Clinical Excellence
(NICE) [5]. Eligibility to start and to remain on an anti-
TNF drug is determined by the 28 joint-count disease-
activity score (DAS28) [6]. For example, as well as having
tried and failed to respond to two previous disease-
modifying antirheumatic drugs (DMARDs), individuals
must also have a DAS28 > 5.1 on two separate occasions
at least 1 month apart, indicating severe disease activity,
before they become eligible for anti-TNF treatment.
The DAS28 can incorporate one of two inflammatory
markers, erythrocyte sedimentation rate (ESR; DAS28-
ESR) or C-reactive protein (CRP; DAS28-CRP) [7]. CRP
is an acute-phase protein that is produced by the liver
and is very sensitive to short-term changes in inflamma-
tion [8]. In contrast, the level of ESR, an indicator of
long-standing, chronic inflammation, is an indirect mea-
sure of acute-phase protein and has a slow response after
inflammatory stimulation or resolution [8]. ESR is also
sensitive to anemia and non-acute-phase proteins such as
immunoglobulin and rheumatoid factor (RF), and thus
may be a better indicator of disease severity than CRP
[9]. However, as the level of ESR varies with age and gen-
der, this may confound DAS28-ESR measurements [8,9].
CRP is encoded by the CRP gene (CRP) on chromosome
1q21-q23. Recent genetic studies investigating this locus
have shown that several single nucleotide polymorphisms
(SNPs), and haplotypes of these variants, explain some of
the variation in the level of serum CRP at baseline levels,
as well as the variation in response to acute inflammatory
stimuli [10-15]. This has led investigators to question
whether genetic variants at the CRP locus correlate with
the level of CRP in the setting of chronic inflammation
[15]. Indeed, a recent study by Rhodes et al. (2010)
observed that haplotypes of common SNPs within the
CRP locus were correlated with CRP levels in two cohorts
of patients with RA [16], although it should be noted that
both cohorts had modestly active disease as determined by
their median CRP levels (11 mg/L and 5 mg/L in the dis-
covery and replication cohorts, respectively) [16]. If this
correlation is also observed in patients with high CRP
levels, it could have important clinical implications when
assessing eligibility for anti-TNF therapy, using the
DAS28-CRP [8].
The aim of the current work was first, to investigate the
importance of CRP genetic variants in influencing CRP
levels in UK patients with RA with very active disease,
and second, to determine whether the genetic variants
correlated with treatment response to anti-TNF drugs.
Specifically, we aimed to investigate haplotypes at the
CRP gene defined by three variants (rs1205, rs1800947 &
rs3091244), which have previously been associated with
levels of CRP production, to determine their association
with baseline CRP levels, baseline DAS28-CRP and
change in DAS28-CRP in patients with RA before and
after 6 months therapy with an anti-TNF drug.
Methods
Subjects
DNA samples from patients included in this study were
obtained from the Biologics in Rheumatoid Arthritis
Genetics and Genomics Study Syndicate (BRAGGSS).
Patients eligible for the BRAGGSS cohort were initially
identified through the British Society for Rheumatology
Biologics Register (BSRBR). The BSRBR was launched in
October 2001 and is a prospective observational study of
patients with rheumatic diseases newly commenced on
anti-TNF biologic therapy, who are followed up every
6 months for a period of at least 5 years [17,18]. One of
the fundamental objectives of the BSRBR is to monitor
patient progress, as well as the incidence of long- and
short-term side effects [19,20].
The BRAGGSS cohort was developed for the study of
genetic predictors of response to anti-TNF biologic ther-
apy. Consultants at contributing centers across the UK
gave permission to identify their patients from the
BSRBR; eligible patients were approached by letter and
invited to donate blood samples for DNA extraction and
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serum when they were due for a routine blood test.
Samples were posted to the Arthritis Research UK Epide-
miology Unit for processing, storage, and analysis. All
contributing patients provided informed consent, and the
study was approved by a multicenter ethics committee
(COREC 04/Q1403/37) [20].
The patient-inclusion criteria for BRAGGSS are as fol-
lows: a diagnosis of RA; registration with the BSRBR;
planned treatment with an anti-TNF; and Caucasian ori-
gin. In addition, a baseline and 6-month DAS28 is
recorded to allow subsequent analysis.
Patients were excluded from this study if they had
stopped treatment because of adverse events or reasons
other than inefficacy, or after any change in their anti-
TNF biologic therapy during the follow-up period [21].
Genotyping
Genotyping for the rs1205 SNP was performed by using
the Sequenom MassARRAY iPLEX system in accor-
dance with the manufacturer’s instructions [22].
DNA samples for the rs1800947 SNP and the triallelic
rs3091244 SNP were genotyped by using TaqMan PCR
Genotyping Assay. The primer and probe sequences for
the rs3091244 assay were retrieved from the literature
[23], and the rs1800947 SNP assay was available from the
manufacturer. Genotyping for both SNPs was performed
in accordance with the manufacturer’s instructions [24].
For each marker, negative water controls were included
for each experiment, and genotype cluster plots were
manually reviewed. In addition, SNPs were assessed for
deviation from Hardy-Weinberg Expectation (HWE).
Haplotype inference
Haplotypes were estimated by using the expectation
maximization (EM) algorithm implemented in the
haplo.stats package within the R statistical environment
[25]. This software supports the inclusion of SNPs with
more than two alleles (that is, rs3091244).
Statistics
Baseline levels of CRP in the cohort studied did not fol-
low a normal distribution and were positively skewed;
thus baseline CRP values were log-transformed before
analysis. The association between SNPs (and haplotypes
of SNPs) and CRP was evaluated with linear regression.
For the analysis of genotypic effects at each SNP, the
common allele homozygous genotype was selected as the
comparison group. For SNPs in which the homozygote
minor allele genotype was seen fewer than 5 times,
homozygote minor and heterozygote genotypes were
combined.
Haplotype effects on baseline log-transformed CRP
levels were determined with linear regression. The effect
of each haplotype was calculated relative to those
homozygous for H5, and the geometric mean values
presented are the predicted values for homozygous sub-
jects with each of the other haplotypes.
Analyses were repeated, adjusting for baseline ESR, a
marker of background inflammation, independent of the
influence of functional variation at the CRP gene. As
baseline ESR levels did not follow a normal distribution
and were positively skewed, ESR was square-root trans-
formed before analysis. The relation between the trans-
formed CRP and ESR was assessed and found to be
linear. After regression analysis, baseline CRP values
were derived by back-transforming the regression para-
meters and are reported as geometric mean values.
Linear regression models were also used to analyze
DAS28-CRP and change in DAS28-CRP.
These analyses were performed by using STATA v.10
[26].
Power calculations were performed by using Quanto
(version 1.2.3) [27] under an additive model for a range
of marker-allele frequencies.
Results
Clinical response and demographic data were available
for 2,767 patients, of whom 393 were ineligible for ana-
lysis: 244 stopped anti-TNF treatment for reasons other
than inefficacy, 11 had no recorded information regard-
ing a potential change in their therapy, and 138 had
missing baseline or 6-month response DAS28 data.
The rs1205, rs1800947, and rs3091244 SNP markers
were genotyped in 1,612 DNA samples. The genotyping
success rate for rs1205, rs1800947, and rs3091244 was
93%, 96%, and 93%, respectively.
In total, 1,374 samples were successfully genotyped for
all three SNPs, and baseline (pretreatment) CRP serum
measurements were available for 599 (Table 1). Geno-
type frequencies at all three CRP markers conformed to
HWE (Table 2).
Haplotypes were estimated for all 1,374 samples, and
haplotype frequencies were in keeping with those
reported in the literature [15] (Table 3). All haplotypes
were estimated with > 98% accuracy (data not shown).
Three individuals were removed from subsequent ana-
lyses because of the absence of one of the five common
haplotypes (Table 3).
For 442 individuals for whom change in DAS28-CRP
data was available, the study had > 80% power (at the
5% significance threshold) to detect a clinically meaning-
ful difference of 0.6 DAS28-CRP Units for an allele fre-
quency of 5%.
No significant association was seen between any of the
markers investigated and baseline CRP levels (Table 2).
As rs3091244 is triallelic, two analyses were performed
with each minor allele, T and A (Table 2). No association
was observed between CRP haplotypes and baseline CRP
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(P = 0.593) (Table 3). Further, no association was found
between CRP haplotypes and baseline DAS28-CRP (P =
0.540), or change in DAS28-CRP after 6 months treat-
ment with anti-TNF therapy (P = 0.302) (Table 3).
Adjustment for ESR did not qualitatively affect these
findings (data not shown).
Not surprisingly, we noted a decrease in serum CRP
levels within our cohort after 6 months of treatment with
an anti-TNF, which approached the normal range (med-
ian CRP, 10 mg/L (IQR, 5, 26)). However, no association
was seen between any of the markers investigated and
CRP levels 6 months after treatment at the 5% signifi-
cance threshold (data not shown). Further, no association
was noted between CRP haplotypes and serum CRP
levels 6 months after treatment (P = 0.17), or an associa-
tion between CRP haplotypes and change in serum CRP
levels 6 months after treatment (P = 0.19) (data not
shown).
Finally, for the same 599 individuals for whom base-
line CRP data were available, age at baseline (in years)
and gender (female) were significantly associated with
baseline levels of ESR (P = 0.001 and P = 0.012, respec-
tively), baseline DAS28-ESR (P = 0.044 and P = 0.002,
respectively) and change in DAS28-ESR (P = 0.0002 and
P = 0.0062, respectively). However, age at baseline and
gender did not significantly correlate with baseline CRP,
DAS28-CRP, or change in DAS28-CRP (data not
shown).
Discussion
Recent reports have identified functional variants at the
CRP locus that affect basal CRP production, and thus
basal levels in a population can vary. This has poten-
tially important consequences for RA patients. Eligibility
for treatment with anti-TNF drugs is determined by use
of the DAS28, which may incorporate CRP as a marker
of acute-phase inflammation. Therefore, if genetic mar-
kers at the CRP locus affect CRP levels, these markers
could influence treatment decisions, which may be parti-
cularly important in patients who carry the genotype
that is correlated with low CRP production, as they may
be less likely to meet eligibility criteria for anti-TNF
therapy. The current study is the first to investigate the
correlation between CRP functional SNP markers and
response to treatment in a cohort of UK patients with
very active disease.
In contrast to previous investigations, none of the SNP
markers or marker haplotypes investigated at the CRP
gene correlated with serum CRP level. A previous study
by Suk Danik et al. (2006), observed correlation between
each of the three SNPs investigated in the current study
and median levels of CRP after an acute ischemic event,
Table 1 Demographic and disease characteristics
(n = 599)
Agea (years) 56.81 (10.84)
Disease durationb (years) 12 (20-6)
Sex,a F (%) 457 (76.29)
CRP at baseline, median (IQR) mg/Lb 34 (17-63)
ESR at baseline, median (IQR) mg/Lb 43 (27-68)
DAS28 at baselinea 6.36 (0.90)
Change in DAS28a -2.01 (1.23)
Concurrent DMARD n (%) 449 (74.96)
Infliximab 272 (45.41)
Etanercept 220 (36.73)
Adalimumab 107 (17.86)
CRP, C-reactive protein; DAS28, Disease Activity Score 28; DMARD, disease-
modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; F, female;
IQR, interquartile range; SD, standard deviation. aValues are expressed as
mean (SD). bValues are expressed as median (IQR). All other values are n (%).
Disease duration was measured in 598 patients; erythrocyte sedimentation
rate (ESR) levels were measured in 578 patients; and change in DAS28 was
measured in 442 patients.
Table 2 Relation of CRP genotypes to baseline CRP levels
SNP HWE (p) Genotype Geometric mean CRP (mg/L) (SD) n P value
rs1205 0.60 GG 32.17 (2.75) 272 Ref.
GA 31.51 (2.67) 270 0.81
AA 26.39 (2.70) 57 0.17
rs1800947† 0.23 CC 31.93 (2.70) 533 Ref.
CG 26.47 (2.76) 66 0.15
rs3091244_T 0.33‡ XX 29.09 (2.73) 278 Ref.
XT 34.40 (2.72) 261 0.05
TT 28.94 (2.53) 60 0.97
rs3091244_A¶ XX 31.36 (2.70) 550 Ref.
XA 30.32 (2.68) 33 0.85
SNP, single-nucleotide polymorphism; HWE, Hardy-Weinberg Expectation; SD, standard copies of T allele. For the A allele of rs3091244: XX, no copies of A allele;
XA one copy of A allele; AA two copies of A allele.
† No homozygote minor allele observed in this dataset.
‡ rs3091244_T & rs3091244_A SNPs combined to give HWE of rs3091244.
¶ Homozygote minor alleles grouped with heterozygotes.
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in which the median CRP value was 11.5 mg/L (IQR,
4.74, 27.69) [28]. That study reported that individuals
carrying the rare homozygous AA genotype in
rs3091244 had fivefold higher CRP levels than did those
who did not [28]. In the current study, the AA genotype
at rs3091244 was observed in only three individuals,
thus making interpretation of between-study differences
difficult. The most likely explanation for the differences
seen between the current study and that of Suk Danik
et al. (2006) is that any effect of the genetic markers on
CRP levels is less important in more-active disease; in
the current study of RA patients with longstanding
(median, 12 years) disease, CRP levels were much higher
(median CRP, 34 mg/L (IQR, 17, 63), Table 1; see Addi-
tional File 1).
A recent study by Rhodes et al. (2010) reported an
association between CRP haplotypes and levels of CRP in
RA patients [16]. Although the article concluded that
CRP functional SNPs influence CRP level in patients with
RA, the patients included in their investigation had mod-
estly active disease, with median CRP levels of 11 mg/L
and 5 mg/L in the discovery and replication cohorts,
respectively [16].
The effect of inflammatory mediators (such as IL-6)
and corresponding levels of inflammation may have a
role in masking the effect of CRP SNPs on the level of
serum CRP. As inflammation settles, levels of other
inflammatory markers decrease, which could allow subtle
genetic effects to be more clearly observed. However,
within our cohort, although posttreatment levels of CRP
approached levels (median CRP, 10 mg/L (IQR 5, 26)) in
keeping with those reported by Rhodes et al. (2010), no
significant genetic association was detected between any
of the SNP markers or haplotypes investigated, and CRP
levels at baseline or 6 months after treatment (data not
shown). Indeed, 6 months may not be a sufficient time to
detect a genetic effect if inflammation has not been com-
pletely terminated. Prospectively collected cohorts from
which CRP measurements have been collected beyond 6
months after treatment will be needed to investigate this
possibility.
Failure to detect an association may reflect inadequate
power, particularly when investigating genotypic effects
with low minor-allele frequency SNPs, suggesting that
the current study may be underpowered to detect mod-
est effects. However, despite not reaching statistical sig-
nificance, the direction and strength of effect for some
SNPs, for example, rs1205 and rs1800947, were in keep-
ing with previously reported trends in association stu-
dies. Further, the sample size investigated had > 80%
power to detect a change in DAS28 of 0.6 units, a
meaningful difference at the 5% threshold. Genotyping
success was > 90% for all three SNP markers, and haplo-
type estimation achieved > 98% accuracy. Moreover,
haplotype frequencies corresponded well with those pre-
viously reported in the literature [15].
In the context of previous studies, such an observed
lack of association may be influenced by 75% of indivi-
duals receiving concurrent DMARD therapy. However,
despite the majority of individuals taking DMARDs,
levels of CRP remained very high, indicating very active
disease. Such variation in the current cohort may be
partly explained by, first, the significant nonresponse
rate seen in some individuals treated with DMARDs,
and second, the necessity of nonresponse to DMARDs
to satisfy the stringent anti-TNF eligibility criteria in the
UK.
Recently, a number of other genetic variants have
been shown to correlate with CRP levels in the general
population [29]. In the future, it will be interesting to
investigate the effect of these variants in influencing
baseline and changes in CRP in RA patients receiving
anti-TNF therapy, although it should be noted that the
largest single effect on CRP levels is determined by var-
iants in CRP. Hence, larger sample sizes will be required
for future studies of these other loci.
Conclusions
In summary, although genetic variation has been shown
to influence CRP levels in the normal range, no evi-
dence supports that such variation affects the levels of
CRP in patients with very active inflammation. Certainly,
Table 3 CRP haplotype frequency, mean baseline CRP, DAS28, and change in DAS28
H1 G C T 0.31 34.01
(28.28, 40.91)
6.37
(6.20, 6.54)
-1.95
(-1.69, -2.21)
H2 A C C 0.27 29.91
(24.34, 36.78)
6.28
(6.09, 6.46)
-1.81
(-1.51, -2.01)
H3 G C C 0.31 31.87
(26.63, 38.14)
6.37
(6.20, 6.53)
-2.13
(-1.87, -2.38)
H4 G C A 0.05 30.32
(18.04, 50.96)
6.73
(6.26, 7.20)
-2.32
(-1.59, -3.06)
H5 A G C 0.06 21.97
(13.46, 35.86)
6.33
(5.89, 6.78)
-2.46
(-1.76, -0.15)
CI, confidence interval; CRP, C-reactive protein; DAS28, 28-joint-count disease-activity score.
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we have observed from the current study that genetic
variation at the CRP locus does not influence baseline
CRP, baseline DAS28-CRP, or change in DAS28-CRP.
We and others previously reported that age at baseline
and gender influence both baseline DAS28 and change
in DAS28 after 6 months of therapy [30,31]. In the cur-
rent study, we confirm the known association of age
and gender with baseline ESR levels but show no asso-
ciation of these factors with baseline CRP levels. There-
fore, and most important, these findings strengthen the
case for the use of DAS28-CRP in place of DAS28-ESR
to assess eligibility for, and treatment response to anti-
TNF medication in patients with active RA.
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